PUBLIC COMPANY
save$DSGNDesign Therapeutics, Inc.
$DSGN14.66+0.27%Carlsbad, CA, USupdated 5h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
- phase2A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
- phase1A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
- phase1Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
Insider activity
source: SEC Form 4routine RSU / option mechanics (2)
- Mar 31, 26grantShapiro David · 60,000 sh
- Mar 31, 26grantShapiro David · 7,500 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that